NCT06960993 Mosaic Trial for Stem Cell Transplant Recipients
| NCT ID | NCT06960993 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Hematologic Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 356 participants |
| Start Date | 2025-04-28 |
| Primary Completion | 2028-06-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 356 participants in total. It began in 2025-04-28 with a primary completion date of 2028-06-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with a hematologic cancer according to medical records * Scheduled for or preparing for scheduling of an allogeneic or autologous stem cell transplant at one of our study sites * Aged 18 or older (no upper limit) * English or Spanish Proficient * Interested in using a website to learn about stem cell transplant * Ability to understand and willingness to sign an informed consent document and comply with all study procedures Exclusion Criteria: * Currently participating in a behavioral intervention targeting distress, health-related quality of life, or symptoms * Undergoing the first in a planned tandem stem cell transplant * Unable to provide meaningful consent (severe cognitive impairment or language difficulties)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06960993 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06960993 currently recruiting?
Yes, NCT06960993 is actively recruiting participants. Contact the research team at christine.rini@northwestern.edu for enrollment information.
Where is the NCT06960993 trial being conducted?
This trial is being conducted at Washington D.C., United States, Chicago, United States, Nutley, United States.
Who is sponsoring the NCT06960993 clinical trial?
NCT06960993 is sponsored by Northwestern University. The trial plans to enroll 356 participants.